What Researchers Did
The researchers conducted a review of published evidence regarding the classification, incidence, and treatment of osteoradionecrosis (ORN), with a focus on randomized trials of hyperbaric oxygen (HBO) therapy.
What They Found
They found that despite hyperbaric oxygen (HBO) being a standard practice for osteoradionecrosis (ORN) in many units, the evidence base supporting its use remains remarkably weak. Furthermore, published evidence is controversial due to trial protocols not consistently aligning with generally advocated HBO usage.
What This Means for Canadian Patients
Canadian patients undergoing treatment for head and neck cancer should be aware that while hyperbaric oxygen therapy is used for osteoradionecrosis, the scientific evidence supporting its effectiveness is not strong. This suggests that treatment decisions for ORN should be carefully discussed with their healthcare providers, considering the current state of evidence.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A key limitation highlighted by this review is the remarkably weak evidence base and controversial trial protocols for hyperbaric oxygen therapy in osteoradionecrosis.